atrasentan has been researched along with Alloxan Diabetes in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Baelde, HJ; Bajema, IM; Bos, M; Bruijn, JA; Dijkstra, KL; van Aanhold, CCL; van den Berg, BM; Wolterbeek, R | 1 |
| Batlle, D; Chou, JC; Fawzi, AA; Rollins, SD; Ye, M | 1 |
| Avramut, MC; Boels, MG; Dane, MJ; Gröne, HJ; Koster, AJ; Koudijs, A; Lee, DH; Rabelink, TJ; van den Berg, BM; van der Vlag, J; van Faassen, E; van Zonneveld, AJ | 1 |
| Harris, NR; Leskova, W; Wang, Z; Yadav, AS | 1 |
| Boesen, EI; Pollock, DM; Pollock, JS; Saleh, MA; Savin, VJ | 1 |
| Pollock, DM; Pollock, JS; Saleh, MA | 1 |
| Brunner, F; Kirchengast, M; Saad, Z; Stessel, H; Wölkart, G | 1 |
| Carmines, PK; Hobbs, JL; Pollock, DM; Pollock, JS; Sasser, JM; Sullivan, JC; Yamamoto, T | 1 |
| Banes-Berceli, AK; Ketsawatsomkron, P; Marrero, MB; Ogbi, S; Patel, B; Pollock, DM | 1 |
| Brunner, F; Kirchengast, M; Pang, X; Stessel, H; Wölkart, G | 1 |
| Calzadilla, SV; Dayton, BD; Jarvis, MF; Kowaluk, EA; Lynch, JJ; Opgenorth, TJ; Padley, RJ; Wessale, JL; Zhu, CZ | 1 |
11 other study(ies) available for atrasentan and Alloxan Diabetes
| Article | Year |
|---|---|
Reduced Glomerular Endothelial Thrombomodulin Is Associated with Glomerular Macrophage Infiltration in Diabetic Nephropathy.
Topics: Animals; Atrasentan; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Endothelium; Fibrosis; Humans; Inflammation; Kidney; Kidney Glomerulus; Macrophages; Male; Mice; Mice, Knockout; Thrombomodulin | 2021 |
Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice.
Topics: Animals; Apoptosis; Atrasentan; Cell Count; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin Receptor Antagonists; Endothelin-1; Female; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Inbred C57BL; Pyrrolidines; Retinal Ganglion Cells; Retinal Vessels | 2014 |
Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy.
Topics: Albuminuria; Animals; Atrasentan; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin Receptor Antagonists; Glomerular Filtration Rate; Kidney Glomerulus; Male; Mice; Mice, Knockout; Pyrrolidines | 2016 |
Attenuation of streptozotocin-induced microvascular changes in the mouse retina with the endothelin receptor A antagonist atrasentan.
Topics: Administration, Oral; Animals; Atrasentan; Blood Flow Velocity; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin A Receptor Antagonists; Endothelin-1; Fluorescent Antibody Technique, Indirect; Male; Mice; Mice, Inbred C57BL; Platelet Endothelial Cell Adhesion Molecule-1; Pyrrolidines; Regional Blood Flow; Retinal Vessels | 2010 |
Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes.
Topics: Animals; Atrasentan; Diabetes Mellitus, Experimental; Disease Models, Animal; Endothelin A Receptor Antagonists; Immunoassay; Kidney Glomerulus; Male; Membrane Proteins; Oligopeptides; Piperidines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A | 2011 |
Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease.
Topics: Animals; Atrasentan; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Male; Pyrrolidines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Stereoisomerism; Sulfonamides | 2011 |
Cardioprotective effects of atrasentan, an endothelin-A receptor antagonist, but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase.
Topics: Acetylcholine; Animals; Antioxidants; Atrasentan; Cardiotonic Agents; Coronary Vessels; Diabetes Complications; Diabetes Mellitus, Experimental; Endothelin A Receptor Antagonists; Female; Heart; Heart Rate; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microcirculation; Models, Animal; Muscle Cells; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Norepinephrine; Organ Specificity; Pyrrolidines; Streptozocin | 2006 |
Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism.
Topics: Animals; Atrasentan; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Inflammation; Kidney; Male; Oxidative Stress; Prostaglandins; Pyrrolidines; Rats; Rats, Sprague-Dawley; Superoxides | 2007 |
Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrasentan; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelin A Receptor Antagonists; Endothelin-1; Enzyme Activation; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Male; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Pyrrolidines; Rats; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Tetrazoles; Time Factors; Tyrphostins; Vasodilation | 2007 |
Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Endothelin A Receptor Antagonists; Female; Fibrosis; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Oxidative Stress; Pyrrolidines; Ramipril; Rats; Rats, Sprague-Dawley; Streptozocin; Ventricular Function, Left; Ventricular Pressure | 2007 |
ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain.
Topics: Analgesics, Non-Narcotic; Animals; Atrasentan; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Endothelin Receptor Antagonists; Humans; Male; Pain; Pain Measurement; Physical Stimulation; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Stereoisomerism; Vasoconstrictor Agents | 2000 |